Showing results (71-80 of 94) with videos related to
Sort By:
Pageof 10
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|March 1, 2006
Blue-dye intraoperative sentinel lymph node mapping in early non-small cell lung cancerW Rzyman, O M Hagen, R Dziadziuszko, et al.Lung Cancer (Amsterdam, Netherlands)|February 13, 2001
Serum p53 antibodies in small cell lung cancer: the lack of prognostic relevanceE Jassem, J Bigda, R Dziadziuszko, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 12, 2005
First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicenter, randomized, phase III studyO Feher, P Vodvarka, J Jassem, et al.European Journal of Cancer (Oxford, England : 1990)|December 25, 2004
Prevalence and clinical correlations of BRCA1/BRCA2 unclassified variant carriers among unselected primary ovarian cancer cases - preliminary reportEwa J Majdak, Geertruida H De Bock, Izabela Brozek, et al.Head & Neck|September 15, 2005
Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501)Jacques Bernier, Jay S Cooper, T F Pajak, et al.Advances in Medical Sciences|January 24, 2014
Molecular profiles of non-small cell lung cancers in cigarette smoking and never-smoking patientsA Szymanowska-Narloch, E Jassem, M Skrzypski, et al.Journal of the National Cancer Institute|June 8, 2000
Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized studyJ G Klijn, L V Beex, L Mauriac, et al.Anti-Cancer Drugs|January 22, 1998
A multicenter study of recombinant human erythropoietin (epoetin alpha) in the management of anemia in cancer patients receiving chemotherapyM Pawlicki, J Jassem, P Bösze, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 6, 2011
A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancerC Manegold, N van Zandwijk, A Szczesna, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 15, 2014
Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancerG V Scagliotti, I Bondarenko, F Blackhall, et al.Pageof 10